Logo image of ALNY

ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Fundamental Analysis

NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD

418.91  -0.64 (-0.15%)

After market: 418.91 0 (0%)

Fundamental Rating

3

Taking everything into account, ALNY scores 3 out of 10 in our fundamental rating. ALNY was compared to 551 industry peers in the Biotechnology industry. ALNY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALNY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALNY has reported negative net income.
In the past year ALNY has reported a negative cash flow from operations.
ALNY had negative earnings in each of the past 5 years.
In the past 5 years ALNY reported 4 times negative operating cash flow.
ALNY Yearly Net Income VS EBIT VS OCF VS FCFALNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

1.2 Ratios

The Return On Assets of ALNY (-6.99%) is better than 86.39% of its industry peers.
Looking at the Return On Equity, with a value of -127.33%, ALNY is in line with its industry, outperforming 40.83% of the companies in the same industry.
Industry RankSector Rank
ROA -6.99%
ROE -127.33%
ROIC N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNY Yearly ROA, ROE, ROICALNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

ALNY has a better Gross Margin (83.64%) than 87.48% of its industry peers.
ALNY's Gross Margin has been stable in the last couple of years.
ALNY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
ALNY Yearly Profit, Operating, Gross MarginsALNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALNY has more shares outstanding than it did 1 year ago.
ALNY has more shares outstanding than it did 5 years ago.
ALNY has a better debt/assets ratio than last year.
ALNY Yearly Shares OutstandingALNY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ALNY Yearly Total Debt VS Total AssetsALNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

An Altman-Z score of 6.35 indicates that ALNY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.35, ALNY is in the better half of the industry, outperforming 79.13% of the companies in the same industry.
ALNY has a Debt/Equity ratio of 4.10. This is a high value indicating a heavy dependency on external financing.
ALNY has a Debt to Equity ratio of 4.10. This is amonst the worse of the industry: ALNY underperforms 83.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.1
Debt/FCF N/A
Altman-Z 6.35
ROIC/WACCN/A
WACC10.86%
ALNY Yearly LT Debt VS Equity VS FCFALNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

ALNY has a Current Ratio of 2.80. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.80, ALNY is doing worse than 67.15% of the companies in the same industry.
ALNY has a Quick Ratio of 2.75. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a worse Quick ratio (2.75) than 66.06% of its industry peers.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.75
ALNY Yearly Current Assets VS Current LiabilitesALNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALNY have decreased strongly by -311.67% in the last year.
The Revenue has been growing slightly by 5.02% in the past year.
The Revenue has been growing by 59.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-311.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292.31%
Revenue 1Y (TTM)5.02%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%17.26%

3.2 Future

The Earnings Per Share is expected to grow by 62.06% on average over the next years. This is a very strong growth
ALNY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.14% yearly.
EPS Next Y36.07%
EPS Next 2Y63.67%
EPS Next 3Y70.23%
EPS Next 5Y62.06%
Revenue Next Year31.83%
Revenue Next 2Y31.74%
Revenue Next 3Y30.1%
Revenue Next 5Y28.14%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALNY Yearly Revenue VS EstimatesALNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ALNY Yearly EPS VS EstimatesALNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 284.41, which means the current valuation is very expensive for ALNY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALNY indicates a rather cheap valuation: ALNY is cheaper than 87.30% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.28, ALNY is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 284.41
ALNY Price Earnings VS Forward Price EarningsALNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNY Per share dataALNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ALNY's earnings are expected to grow with 70.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.67%
EPS Next 3Y70.23%

More info and screens

0

5. Dividend

5.1 Amount

ALNY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALNYLAM PHARMACEUTICALS INC

NASDAQ:ALNY (8/5/2025, 8:00:00 PM)

After market: 418.91 0 (0%)

418.91

-0.64 (-0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners97.14%
Inst Owner Change-0.07%
Ins Owners0.19%
Ins Owner Change5.25%
Market Cap54.62B
Analysts78.5
Price Target424.24 (1.27%)
Short Float %2.7%
Short Ratio3.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.63%
Min EPS beat(2)34.98%
Max EPS beat(2)58.28%
EPS beat(4)3
Avg EPS beat(4)23.76%
Min EPS beat(4)-2.21%
Max EPS beat(4)58.28%
EPS beat(8)7
Avg EPS beat(8)55.38%
EPS beat(12)9
Avg EPS beat(12)30.63%
EPS beat(16)9
Avg EPS beat(16)17.7%
Revenue beat(2)1
Avg Revenue beat(2)7.46%
Min Revenue beat(2)-0.56%
Max Revenue beat(2)15.49%
Revenue beat(4)1
Avg Revenue beat(4)1.67%
Min Revenue beat(4)-7.88%
Max Revenue beat(4)15.49%
Revenue beat(8)4
Avg Revenue beat(8)19.36%
Revenue beat(12)6
Avg Revenue beat(12)11.5%
Revenue beat(16)7
Avg Revenue beat(16)6.42%
PT rev (1m)2.48%
PT rev (3m)4.99%
EPS NQ rev (1m)2.41%
EPS NQ rev (3m)20.23%
EPS NY rev (1m)-0.82%
EPS NY rev (3m)21.15%
Revenue NQ rev (1m)2.86%
Revenue NQ rev (3m)3.53%
Revenue NY rev (1m)2.28%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 284.41
P/S 22.19
P/FCF N/A
P/OCF N/A
P/B 217.97
P/tB 217.97
EV/EBITDA N/A
EPS(TTM)-2.47
EYN/A
EPS(NY)1.47
Fwd EY0.35%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS18.88
BVpS1.92
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.99%
ROE -127.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.64%
FCFM N/A
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score2
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 4.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.69%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.75
Altman-Z 6.35
F-Score2
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-311.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292.31%
EPS Next Y36.07%
EPS Next 2Y63.67%
EPS Next 3Y70.23%
EPS Next 5Y62.06%
Revenue 1Y (TTM)5.02%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%17.26%
Revenue Next Year31.83%
Revenue Next 2Y31.74%
Revenue Next 3Y30.1%
Revenue Next 5Y28.14%
EBIT growth 1Y-275.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year278.47%
EBIT Next 3Y156.88%
EBIT Next 5Y132.55%
FCF growth 1Y90.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.71%
OCF growth 3YN/A
OCF growth 5YN/A